OTR Therapeutics

Company Drug

OTR Therapeutics Secures NMPA Approval for Phase Ib/II Trial of OTR-8100 – Best-in-Class Small Molecule Inhibitor for Malignant Tumors

Fineline Cube May 26, 2026

OTR Therapeutics announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate...

Company Deals

Zealand Pharma and OTR Therapeutics Seal $2.5 Billion Metabolic Disease Partnership

Fineline Cube Dec 11, 2025

OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A/S (NASDAQ: ZEAL)...

Company Deals

OTR Therapeutics Series-A Raises $100M for Neurology Pipeline

Fineline Cube Dec 8, 2025

OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...

Company Drug

China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China

Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Company Drug

Biokin Secures World’s First EGFR×HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma

Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted